Intervention
Nicotinamide mononucleotide
Research Observatory
Evidence Update
Current evidence
Nicotinamide mononucleotide (NMN), a different compound from nicotinamide riboside, was compared at 250 mg/day with placebo in a small trial of postmenopausal women with prediabetes. NMN improved a skeletal-muscle insulin-sensitivity readout in a small trial of prediabetic postmenopausal women, without establishing diabetes prevention or generalized metabolic rejuvenation.
What changed
The small prediabetic-women trial adds muscle insulin-sensitivity context, not a general functional-benefit claim.
What did not change
No diabetes-prevention, sarcopenia-prevention or aging-reversal claim is supported.
Why it matters
A tissue-specific physiological response does not establish prevention of diabetes or disability.
Main limitation
Hepatic/adipose insulin sensitivity and body-composition changes were not established; no clinical-incidence endpoint and limited sex/metabolic generalizability.
Next proof
Larger diverse trial measuring sustained clinical outcomes.
Summary
Nicotinamide mononucleotide (NMN), a different compound from nicotinamide riboside, was compared at 250 mg/day with placebo in a small trial of postmenopausal women with prediabetes. NMN improved a skeletal-muscle insulin-sensitivity readout in a small trial of prediabetic postmenopausal women, without establishing diabetes prevention or generalized metabolic rejuvenation.
Intelligence Take
A tissue-specific physiological response does not establish prevention of diabetes or disability.
Limitations
Hepatic/adipose insulin sensitivity and body-composition changes were not established; no clinical-incidence endpoint and limited sex/metabolic generalizability.